CEBPalpha mutation analysis

Lab Test name Contact Comments
UZ Brussel - Molecular Hematology CEBPalpha mutation analysis Marleen Bakkus/Barbara Depreter
At diagnosis or relapse: DNA test, PCR (TAD1, TAD2 and bZIP domain) and capillary electrphoresis. Multiplex assay with Flt3-ITD and NPM1 mutation analysis. Consensus primers from working group MolecularDiagnostics.be.
BELAC accreditation number: 141-MED
Version date: 12/04/2023
Accredited:
AZ St-Jan Brugge - Laboratoriumgeneeskunde CEBPalpha mutation analysis dr. Helena Devos/Friedel Nollet, Ph.D.
At diagnosis or relapse: DNA test, PCR (TAD1, TAD2 and bZIP domain) and capillary electrphoresis. Multiplex assay with Flt3-ITD and NPM1 mutation analysis. Consensus primers from working group MolecularDiagnostics.be. DNA sequencing of all three amplicons is performed when at least one insertion/deletion mutation is observed.
Version date: 04/11/2017
UZ Gent CEBPalpha mutation analysis Barbara Denys,
Karl Vandepoele
Simultaneous detection with FLT3-ITD and NPM1
DNA test
BELAC accreditation number 087-MED

CEBPA is also present in our NGS panel for myeloid malignancies
Version date: 18/08/2017
Accredited:
UZ Leuven MolPLUZ CEBPalpha mutation analysis Jolien De Bie
Sample type: blood / bone marrow (EDTA, 2-5 ml)
Frequency: 1x/week
Test type: PCR on DNA, adapted from Benthaus T. et al, Br J Haematol 2008. Can also be performed on RNA.
BELAC accreditation number 215-MED
Accredited:
LHUB-ULB CEBPalpha mutation analysis Pierre Heimann/Laurent Dewispelaere/Pascale Cochaux/Hakim El Housni
SAMPLE TYPE: Peripheral blood (5mL) or bone marrow (EDTA, 1-2 mL)
TRANSPORT: room temperature, within 24h after sampling
FREQUENCY: upon request; max TAT: 4 weeks
TEST TYPE: CEBPa is analyzed in several in-house developed NGS panels designed to refine diagnosis and prognosis of AML, MDS, MPN and MDS/MPN overlap syndrome.
BELAC accreditation number 650-MED
Version date: 04/10/2021
Accredited:
AZ Delta CEBPalpha mutation analysis Geert Martens, Elke Boone
SAMPLE TYPE: blood or bone marrow (1 ml)
FREQUENCY: upon request, at diagnosis or relapse
TEST TYPE: DNA test, PCR (TAD1, TAD2 and bZIP domain) and capillary electrophoresis. Multiplex assay with Flt3-ITD and NPM1 mutation analysis. Consensus primers from working group MolecularDiagnostics.be.
Version date: 05/12/2017
Accredited: